0.861
price down icon1.05%   -0.0091
pre-market  Pre-market:  .90   0.039   +4.53%
loading
Clearside Biomedical Inc stock is traded at $0.861, with a volume of 96,760. It is down -1.05% in the last 24 hours and down -14.75% over the past month. Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$0.8701
Open:
$0.88
24h Volume:
96,760
Relative Volume:
0.39
Market Cap:
$65.30M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-1.6245
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
-11.79%
1M Performance:
-14.75%
6M Performance:
-30.00%
1Y Performance:
-47.18%
1-Day Range:
Value
$0.821
$0.8899
1-Week Range:
Value
$0.821
$0.96
52-Week Range:
Value
$0.7737
$1.9277

Clearside Biomedical Inc Stock (CLSD) Company Profile

Name
Name
Clearside Biomedical Inc
Name
Phone
678-270-3631
Name
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Name
Employee
30
Name
Twitter
@clearsidebio
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
CLSD's Discussions on Twitter

Compare CLSD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLSD
Clearside Biomedical Inc
0.861 65.30M 8.23M -32.49M -19.91M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-21-24 Initiated Chardan Capital Markets Buy
Jun-25-24 Initiated Oppenheimer Outperform
Dec-15-21 Resumed Wedbush Outperform
Jul-29-21 Initiated H.C. Wainwright Buy
May-13-20 Initiated ROTH Capital Buy
Aug-09-19 Downgrade Needham Buy → Hold
Nov-05-18 Downgrade Cowen Outperform → Market Perform
Nov-05-18 Downgrade JP Morgan Overweight → Underweight
Nov-05-18 Downgrade Stifel Buy → Hold
Mar-06-18 Reiterated Needham Buy
May-25-17 Initiated JMP Securities Mkt Outperform
Feb-24-17 Initiated JP Morgan Overweight
Nov-10-16 Reiterated Needham Buy
Oct-24-16 Reiterated Stifel Buy
View All

Clearside Biomedical Inc Stock (CLSD) Latest News

pulisher
Mar 12, 2025

Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan

Mar 12, 2025
pulisher
Mar 09, 2025

Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Mar 06, 2025
pulisher
Mar 06, 2025

Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech

Mar 03, 2025
pulisher
Mar 02, 2025

Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Buys $13,800.00 in Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 25, 2025

Clearside Biomedical director Thorp Clay buys $13,800 in stock By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 24, 2025

Director Makes Bold Move with New Stock Purchase in Clearside Biomedical - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

Clearside Biomedical director Thorp Clay buys $13,800 in stock - Investing.com India

Feb 24, 2025
pulisher
Feb 21, 2025

Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

China accepts Arctic Vision's drug application for eye treatment By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Clearside Biomedical’s partner in China granted acceptance of arcatus NDA - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market? - StockTitan

Feb 20, 2025
pulisher
Feb 18, 2025

Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat

Feb 18, 2025
pulisher
Feb 10, 2025

Clearside reports progress in wet AMD treatment trials - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Clearside Biomedical Announces Additional Data from the - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Clearside reports progress in wet AMD treatment trials By Investing.com - Investing.com Nigeria

Feb 10, 2025
pulisher
Feb 10, 2025

Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients - StockTitan

Feb 10, 2025
pulisher
Feb 09, 2025

Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Selling Your Clearside Biomedical Inc (CLSD) Stock? Here’s What You Need To Know - Stocks Register

Feb 08, 2025
pulisher
Feb 07, 2025

Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat

Feb 07, 2025
pulisher
Feb 05, 2025

Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Feb 05, 2025
pulisher
Feb 04, 2025

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - The Manila Times

Feb 04, 2025
pulisher
Feb 04, 2025

Clearside Biomedical to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Nasdaq

Feb 04, 2025
pulisher
Feb 04, 2025

Clearside Biomedical to Participate in Fireside Chat at the - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Inside Clearside Biomedical's Strategic Vision: CEO Fireside Chat at Major Healthcare Conference - StockTitan

Feb 04, 2025
pulisher
Jan 28, 2025

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences - Nasdaq

Jan 28, 2025
pulisher
Jan 28, 2025

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

Clearside Biomedical Announces Multiple Medical Meeting - GlobeNewswire

Jan 28, 2025
pulisher
Jan 26, 2025

Assenagon Asset Management S.A. Sells 125,190 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Clearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat

Jan 25, 2025
pulisher
Jan 23, 2025

Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat

Jan 23, 2025
pulisher
Jan 22, 2025

Clearside Biomedical Announces its Asia-Pacific Partner, - GlobeNewswire

Jan 22, 2025

Clearside Biomedical Inc Stock (CLSD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):